// App-Quantinova.ai

188 : Long-term Integrated Safety of Patisiran in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy

Researchers

Presenter

  • Julian Gillmore

Principal Investigators

  • John Berk

  • Angela Dispenzieri

  • Michael Polydefkis

  • Alejandra Gonzalez-Duarte

  • Yoshiki Sekijima

  • Marianne T. Sweetser

  • Seth Arum

  • Jing Jing Wang

  • Matthew T. White

  • Mathew Maurer

Medical Centers

  • Kings College London, London, United Kingdom

  • Boston University, Boston, MA

  • Mayo Clinic, Rochester, Rochester, MN

  • Johns Hopkins, Baltimore, MD

  • Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico

  • Shinshu University, Matsumoto, Japan

  • Merrimack Pharmaceuticals, Cambridge, MA

  • Columbia University, New York, NY

Locations

  • United Kingdom

  • United States

  • Mexico

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

Disease

  • Familial Amyloid Polyneuropathy

  • Peripheral neuropathy

  • Amyloid disease

Biomarkers

  • N/A

Drug/Treatment

  • Patisiran

Outcome

  • N/A

Study Design

  • Open Label

Phase

  • III

Study Id's

  • NCT01961921

  • NCT01960348

  • NCT02510261

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved